Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.
-
Aggarwal A
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Parai MK
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Shetty N
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Wallis D
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Woolhiser L
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
-
Hastings C
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
-
Dutta NK
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
-
Galaviz S
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Dhakal RC
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Shrestha R
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Wakabayashi S
Department of Immunology and Infectious Disease, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
-
Walpole C
Structure-guided Drug Discovery Coalition, SGC Toronto, ON, Canada.
-
Matthews D
Structure-guided Drug Discovery Coalition, SGC Toronto, ON, Canada.
-
Floyd D
Structure-guided Drug Discovery Coalition, SGC Toronto, ON, Canada.
-
Scullion P
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, UK.
-
Riley J
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, UK.
-
Epemolu O
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, UK.
-
Norval S
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee, UK.
-
Snavely T
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
-
Robertson GT
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
-
Rubin EJ
Department of Immunology and Infectious Disease, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
-
Ioerger TR
Department of Computer Science and Engineering, Texas A&M University, College Station, TX, USA.
-
Sirgel FA
NRF Centre of Excellence for Biomedical TB Research and the South African MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa.
-
van der Merwe R
NRF Centre of Excellence for Biomedical TB Research and the South African MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa.
-
van Helden PD
NRF Centre of Excellence for Biomedical TB Research and the South African MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Stellenbosch University, Tygerberg, South Africa.
-
Keller P
Institute of Medical Microbiology, National Center for Mycobacteria, University of Zurich, Zurich, Switzerland.
-
Böttger EC
Institute of Medical Microbiology, National Center for Mycobacteria, University of Zurich, Zurich, Switzerland.
-
Karakousis PC
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
-
Lenaerts AJ
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
-
Sacchettini JC
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA. Electronic address: sacchett@tamu.edu.
Show more…
English
Widespread resistance to first-line TB drugs is a major problem that will likely only be resolved through the development of new drugs with novel mechanisms of action. We have used structure-guided methods to develop a lead molecule that targets the thioesterase activity of polyketide synthase Pks13, an essential enzyme that forms mycolic acids, required for the cell wall of Mycobacterium tuberculosis. Our lead, TAM16, is a benzofuran class inhibitor of Pks13 with highly potent in vitro bactericidal activity against drug-susceptible and drug-resistant clinical isolates of M. tuberculosis. In multiple mouse models of TB infection, TAM16 showed in vivo efficacy equal to the first-line TB drug isoniazid, both as a monotherapy and in combination therapy with rifampicin. TAM16 has excellent pharmacological and safety profiles, and the frequency of resistance for TAM16 is ∼100-fold lower than INH, suggesting that it can be developed as a new antitubercular aimed at the acute infection. PAPERCLIP.
-
Language
-
-
Open access status
-
hybrid
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/global/documents/30311
Statistics
Document views: 24
File downloads: